Moderna's R&D expenses fell 27% in the third quarter, mainly due to lower clinical development costs after completion and phasing out of certain late-stage studies in the infectious disease portfolio, as well as continued cost efficiency across the organization.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.